A Multicenter Randomized Open Label Phase II Study Evaluating the Efficacy and the Tolerance of Immunochemotherapy and of Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients with Unresectable Stage III Non Small Cell Lung Cancer
Latest Information Update: 29 Oct 2024
At a glance
- Drugs Carboplatin (Primary) ; Cemiplimab (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SPORADIC
- 29 Oct 2024 New trial record